Skye Bioscience (SKYE)
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and re...
- Open
- 0.2804
- High
- 0.2840
- Low
- 0.2550
- Prev. Close
- 0.2804
- Volume
- 974.58K
- Turnover
- 263.21K
- Avg Price
- 0.2701
- Bid/Ask Ratio
- 44.64%
- Amplitude
- 10.34%
- 52wk High
- 4.9900
- Volume Ratio
- 12.91
- Turnover Ratio
- 4.25%
Skye Bioscience Analyst Rating
View moreForecast & Rating
Aug 17, 2026Price forecast
$7.602614.29%
Forecast & RatingBuy
5analysts
- Strong buy40.00%
- Buy20.00%
- Hold40.00%
- Sell0.00%
- Strong sell0.00%
News
- businessinsider · 6 hours ago
Skye Bioscience Inc trading halted, news pending
- Weekly Review · 7 hours ago
Weekly Recap | Skye Bioscience -44.09%, consensus target far above spot
- PUBT · 1 day ago, 04:57 PM
5AM Partners VII disposes of 375,840 Skye Bioscience shares worth $134,482.80
- PUBT · 2 days ago, 05:07 AM
Skye Bio amends 8-K to set Aug. 24 effective date for reverse stock split
- PUBT · Aug 19 at 05:04 AM
Skye Bioscience flags Nasdaq noncompliance after stockholders’ equity falls to ($497,307)
- Price Alert · Aug 18 at 07:18 AM
Pre-market hot trades in US stocks: Skye Bioscience down 8.36% in pre-market; Cerebras down 3.05% in pre-market
